Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026$535 million in cash, cash equivalents and short-term investments as of ...

SUBCUT HF II, a randomized controlled investigator-sponsored trial of at-home subcutaneous furosemide for heart failure–related edema, meets its primary and key secondary endpoints, supporting the ...

In a double-blind, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the predefined efficacy ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, while ...

Introduction Suicidal ideation is common in young people and increases the risk of suicide. Effective interventions that are relevant and accessible to young people, so-called digital natives, are ...

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment ...

Bone broth and collagen supplements may have benefits for joints, skin, bones, and gut health. Before taking a supplement or ...

Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in ...

Objectives While exercise adherence is known to vary during cancer treatment, little is known about what predicts these ...

Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2026, along with the approximately $323.9 million in net proceeds from our April 2026 ...